2019
DOI: 10.1002/mgg3.1099
|View full text |Cite
|
Sign up to set email alerts
|

The role of race and ethnicity in views toward and participation in genetic studies and precision medicine research in the United States: A systematic review of qualitative and quantitative studies

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Abstract Background: Racial/ethnic minority populations in the United States are consistently underrepresented in genetic research. Large-scale public participation is required to ensure discoveries from precision medicine research … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
63
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 57 publications
(64 citation statements)
references
References 55 publications
(530 reference statements)
1
63
0
Order By: Relevance
“…So, there is a need to perform broad sequencing of global populations in order to enhance known pharmacogenetic variants across underrepresented populations. Underrepresented populations historically have low engagement in genetic medicine, in part due to fear of discrimination or lack of trust, among other barriers 26 . The genomic medicine community needs to continue to work to overcome these barriers and encourage population diversity in studies, submitting discovered pharmacogenetic variants and impact to PharmVar to better represent global populations.…”
Section: Discussionmentioning
confidence: 99%
“…So, there is a need to perform broad sequencing of global populations in order to enhance known pharmacogenetic variants across underrepresented populations. Underrepresented populations historically have low engagement in genetic medicine, in part due to fear of discrimination or lack of trust, among other barriers 26 . The genomic medicine community needs to continue to work to overcome these barriers and encourage population diversity in studies, submitting discovered pharmacogenetic variants and impact to PharmVar to better represent global populations.…”
Section: Discussionmentioning
confidence: 99%
“…Our results highlighted differences in FCH discussions with health care providers by sex, annual household income, education, race and ethnicity, and personal cancer history, suggesting population subgroups that may benefit from targeted and tailored efforts to address common barriers and promote FCH discussions. Previous research noted numerous barriers to patient-provider discussions about family histories, including lack of time during medical appointments, limited knowledge of FCH reported by patients, and lack of systematic collection and interpretation of family history information (16,23). Additionally, complex underlying factors, such as medical mistrust and patient concerns about harmful use of genetic information, present systemlevel barriers to patient-provider communication about FCH among non-White populations (24).…”
Section: Discussionmentioning
confidence: 99%
“…Based on previous evaluations of diversity and inclusion by race and ethnicity, non-White groups have already been established as underrepresented. [4][5][6] It is important to note here a distinction between minority health and underrepresentation of other groups, especially with regards to health disparities research and biomedical research representation. Minority health refers to "health characteristics and attributes of racial and/or ethnic minority groups (defined by Office of Management and Budget), who are socially disadvantaged due in part by being subject to potential discriminatory acts."…”
Section: Introductionmentioning
confidence: 99%